IsoPet® is now commercially available as part of a company-sponsored program to gain experience on the use of the
product and to share the results of this therapy with the veterinary community. Interested animal owners will have this completed form sent to Vivos, Inc CEO | President Dr. Mike Korenko.
University of Missouri Department of Veterinary medicine will review the information and provide their recommendation regarding applicability of IsoPet® therapy.
Important information regarding IsoPet®:
IsoPet® is designed to deliver a high dose of therapeutic radiation at the point of administration with no significant radiation extending beyond the treatment zone. The hydrogel immobilizes the yttrium-90 phosphate particles to prevent any contamination in urine or feces. With a 2.7-day half-life the majority of the dose is administered over the first ten days and then the radioactivity quickly decays.
IsoPet® is most appropriate for treating localized cancers, especially solid tumors with well-defined boundaries or margins. IsoPet® is particularly attractive for treating tumors that would be difficult to remove surgically (non-resectable) but could be reached with a needle for injecting the product.
IsoPet is not effective against distributed cancers, such as lymphomas, or advanced metastatic disease where the cancer has spread significantly beyond the tumor site. IsoPet can only be expected to effectively treat the primary tumor.
You will be participating in a developmental therapy. The therapy has demonstrated limited, but positive results. The data from the tests will be made available to Vivos Inc. and other clinics and could be included in published paper or conferences. Since it is developmental the pet owner recognizes there are risks.
IsoPET® therapy price is competitive with the cost of external beam radiation therapy.